Objective: This study describes the prevalence and characteristics of an elevated resting energy expenditure (REE) in patients with chronic obstructive pulmonary disease (COPD). Design and setting: Patients were consecutively admitted to an in-patient pulmonary rehabilitation centre. Subjects: The study group consisted of 172 (123<) clinically stable patients with COPD, age mean (s.d. ) 64 (10) y). Interventions: REE was assessed by indirect calorimetry (ventilated hood) and adjusted for the in¯uence of fatfree mass (FFM; measured by bioelectrical impedance analysis) using the linear regression equations of REE on FFM generated in 92 healthy age-matched subjects (58<, age 67 (8) y) for men and women separately. The predicted REE adjusted for FFM (REEFFM) was obtained by using the FFM of each individual patient in the linear regression equation of REE on FFM generated in the healthy control group. Results: 26% of the patients were hypermetabolic (de®ned as REE b 110% REEFFM), characterized by a lower age (60 (10) vs 65 (9) y) and a lower total lung capacity (TLC; 122 (27) vs 139 (28)%pred) compared to normometabolic patients (P`0.001). The prevalence of FFM-depletion was equal among normo-and hypermetabolic patients: 36% vs 33% respectively. Depleted patients expressed however a signi®cantly higher residual volume/TLC ratio and a lower maximal inspiratory mouth pressure independently of hypermetabolism (P`0.05). In contrast, on base of the Harris & Benedict (HB) prediction equations, which do not take body composition into account, 54% of the patients were hypermetabolic (REE b 110% REEHB), characterized by a higher age and a lower body mass and FFM (P`0.05). Conclusions: Hypermetabolism commonly occurs in COPD, characterized by less hyperin¯ation at rest, in contrast to the suggested contribution of an elevated oxygen cost of breathing (OCB) to hypermetabolism in COPD. The higher hyperin¯ation at rest in FFM-depleted patients independently of hypermetabolism suggests a higher OCB during activities, contributing to the elevated total daily energy expenditure previously reported in COPD. The HB-equations overestimate the prevalence of hypermetabolism and link hypermetabolism incorrectly to aging and depletion.
Introduction
Weight loss is a common problem in patients with chronic obstructive pulmonary disease (COPD) , compromising fat mass (FM) and fat-free mass (FFM) (Schols et al, 1993) . The clinical importance of weight loss, particularly loss of FFM, has been demonstrated in its adverse effects on physical performance and on respiratory muscle function (Fiaccadori et al, 1988) . Furthermore, weight loss and a low body mass are unfavourable prognostic factors for survival (Schols et al, 1995) .
In general, weight loss is considered as the result of an imbalance between energy intake and energy expenditure. Metabolic derangements seem to be a major cause of the disturbed energy balance leading to weight loss. Furthermore, metabolic changes can lead to selective depletion of FFM despite relative preservation of FM in COPD. Several studies have reported an increased resting energy expenditure (REE) in patients with COPD (Schols et al, 1991a; Hugli et al, 1993; Fitting et al, 1989; Donahoe et al, 1989; Green & Muers, 1991) , but the prevalence and the determining factors of hypermetabolism are yet unknown.
The aim of the present study was to describe the prevalence of hypermetabolism in 172 clinically stable patients with COPD in relation to body composition and lung function. On the one hand, hypermetabolism was de®ned on base of the classically used Harris & Benedict (HB) (1919) prediction equations. On the other hand, hypermetabolism was based on adjustment for FFM in an age-matched healthy control group, since we hypothesized that the HB-equations may not correctly predict REE in patients with COPD due to body compositional changes after weight loss. Furthermore, the relative contribution of hypermetabolism to the prevalence and characteristics of depletion of FFM in patients with COPD was studied.
Methods

Patients
The patient group consisted of patients with COPD consecutively admitted to an in-patient pulmonary rehabilitation centre. According to the ATS (1995) guidelines, patients exhibiting an increase in forced expiratory volume in one second (FEV 1 ) greater than 10% of baseline after inhalation of a b 2 -agonist were excluded from the study. Also patients with confounding disorders such as cancer, unstable cardiac condition, active gastrointestinal abnormalities, recent surgery, endocrine disorders like diabetes mellitus and hyper-ahypothyroidy were excluded from the study. To avoid a possible confounding effect of acute infectious exacerbations of the disease on REE (Vermeeren et al, 1994) , only patients in a stable pulmonary condition were studied; none of the patients had clinical signs of edema, nor were suffering from a respiratory tract infection as based on a negative bacteriological sputum analysis, had fever or showed an increase in symptoms. The ®nal study group consisted of 172 (123<) stable patients with moderate to severe COPD.
Controls
The control group consisted of 92 (58<) healthy, agematched subjects. Volunteers with disorders which might affect metabolic rate (cancer, unstable cardiac condition, gastrointestinal diseases, recent surgery, endocrine disorders and diseases of the respiratory tract) were excluded from the study.
Resting energy expenditure REE was measured by an open circuit indirect calorimetry system using a ventilated hood (Oxycon Beta; Mijnhardt, Bunnik, the Netherlands). The system was calibrated daily at the start of the experiment. The accuracy of the system was regularly assessed using a methanol combustion test. Measurements were started in the early morning (8.30 am). Patients and control subjects were in a fasting state for at least 10 h and had a period of at least 30 min bed rest prior to the measurement during which subjects were comfortably lying on a bed in supine position. Patients received their maintenance inhalation medication 2 h before the measurements started. After stabilization, REE was recorded during a period of 20 min and calculated from oxygen consumption and carbon dioxide production using the abbreviated Weir formula (Weir, 1949) .
Body composition
Body height was determined to the nearest 0.5 cm (Lameris, WM 715, Breukelen, The Netherlands) with subjects standing barefoot. Body mass was assessed with a beam scale to the nearest 0.1 kg (SECA, FRG) with subjects standing barefoot and in light clothing. In 26 controls FFM was calculated from total body water assessment using the deuterium dilution technique described in the Maastricht protocol (Westerterp et al, 1995) . In the other 66 controls as well as in the patient group FFM was measured using single frequency (50 kHz) bioelectrical impedance analysis (BIA; Xitron Technologies, San Diego, USA). Resistance was measured with subjects in supine position. FFM was assessed using the equations of Lukaski et al (1986) for the control subjects and the equation of Schols et al (1991b) for the patients with COPD. FM was calculated by subtracting FFM from body mass. Previously it was established that FFM assessed with BIA was highly correlated with FFM assessed with the deuterium dilution technique in clinically stable patients with COPD (Schols et al, 1991b) .
Lung function FEV 1 was calculated from the¯ow±volume curve using spirometry, and total lung capacity (TLC) and residual volume (RV) were measured plethysmographically (Jaeger, Wu Èrzburg, Germany). Diffusing capacity for carbon monoxide (DLCO) was determined using the single breath method (Jaeger, Wu Èrzburg, Germany). Lung function parameters were expressed as percentage of reference value (Quanjer, 1993) . Arterial blood was drawn by puncture of the brachial artery while patients were at rest and breathing room air; arterial oxygen tension (PaO 2 ) and carbon dioxide tension (PaCO 2 ) were analysed on a blood gas analyser (Radiometer, ABL 330, Copenhagen, Denmark). Respiratory muscle strength was assessed by measuring maximal inspiratory (PI-max) and expiratory (PE-max) mouth pressures according to the method of Black & Hyatt (1969) . PI-max values were noted as positive values.
The study was approved by the medical ethical committee of the University Hospital Maastricht and all subjects gave their informed consent.
Statistics
Analysis of variance was performed to investigate if REE differed between patients and healthy subjects after correction for the covariates sex, age, FFM and FM. Stepwise regression analysis was performed with the independent variables sex, age, FFM and FM in the control group and sex, age, FFM, FM, PaO 2 , PaCO 2 , FEV 1 , TLC and DLCO in the patient group to reveal which parameters could explain the variation in absolute REE. A linear regression equation of REE on FFM was generated in the healthy agematched control group to adjust REE for the in¯uence of FFM. Different equations for men and women were generated, because the regression equations were signi®cantly different between the sexes. The predicted REE adjusted for FFM (REEFFM) for patients was obtained by using the FFM of each individual patient in the linear regression equation of REE on FFM generated in the healthy control group, as earlier described by Schols et al (1991a) . Patients were considered hypermetabolic when measured REE as a percentage of the FFM-based REE (REE/REEFFM) exceeded 110%.
Using the HB-equations for the prediction of REE, patients and controls were considered hypermetabolic when measured REE expressed as a percentage of the HB-equations (REE/REEHB) exceeded 110%.
For comparing parameters between groups the Student's t-test was used for parametric data and the Mann±Whitney U-test for non-parametric data (Altman et al, 1983) . Data were analysed with the computer program`Statistical Package for the Social Sciences' (SPSS).
Results
On analysis of variance, REE was signi®cantly higher in the patients with COPD compared to the healthy agematched control subjects (P 0.013) after correction for the covariates sex, age, FFM and FM (Table 1) .
Controls
The healthy age-matched control group was characterized as follows: age mean (s.d.) 67 (8) Stepwise regression analysis revealed that FFM signi®-cantly explained 65% of the variation in REE in the control group. In addition, sex, FM and age were selected as signi®cant, independent contributors to a total variation in Prevalence of an elevated resting energy expenditure in COPD EC Creutzberg et al REE of 77% (Table 2) . Based on the HB-equations, 24% of the controls were hypermetabolic. Using the linear regression equation of REEaREEHB on REEaREEFFM, a REEaREEFFM of 110% corresponded with a REEaREEHB of 111%.
Patients
In the patient group (age 64 (10) y, BMI 23.7 (4.9) kgam 2 ), stepwise regression analysis revealed that FFM signi®cantly explained 51% of the variation in REE. In addition, age and FM were selected as signi®cant, independent contributors to a total variation in REE of 60%, while lung function was excluded from the model (Table 2) . Using the FFM-based REE generated in the healthy age-matched control group, 26% of the patients were considered hypermetabolic. Hypermetabolic patients were characterized by a signi®cantly lower age and a lower TLC compared to normometabolic patients (Table 3) . Differences in body composition were eliminated after correction for sex and age. Maintenance medication use of the patients did not differ between hypermetabolic and normometabolic patients (theophyllines: 64% vs 68%, b 2 -sympathicomimetics: 96% vs 98%, ipratropium bromide: 84% vs 87%, oral corticosteroids (prednison 10 mg/d): 56% vs 53% and inhalation corticosteroids: 73% vs 79% of the patients respectively). Data concerning the duration of oral corticosteroid use until the measurement of REE were not available, but it may generally be assumed that the patients who were receiving oral corticosteroids at the time of measurement were chronic users; exacerbations of COPD are commonly treated with short courses of high doses of corticosteroids, but the patients in the present study were all in a stable clinical condition. The proportion of patients who were smoking cigarettes was 40% in the hypermetabolic patient group and 20% in the normometabolic patient group (NS).
Using the HB-equations, 54% of the patients were considered hypermetabolic. Using the linear regression equation of REE/REEHB on REE/REEFFM, a REE/ REEFFM of 110% corresponded with a REE/REEHB of 116%. When looking at the differences between patients who were normometabolic on base of both de®nitions of hypermetabolism vs the group that was normometabolic based on REE/REEFFM but hypermetabolic based on REE/REEHB, the latter group was, after correction for sex and age, characterized by a higher age, a lower BMI, a lower FFMI and a lower FM-index (FMI) ( Table 4) .
The prevalence of depletion of FFM, de®ned as FFMI 15(,)/16(<) kg/m 2 , was not signi®cantly different between normo-and hypermetabolic patients with COPD (36% vs 33% respectively; using the FFM-based de®nition of hypermetabolism). Depleted patients expressed, independently of the presence of hypermetabolism, a signi®-cantly higher RV/TLC ratio ( Figure 1a ) and a lower PI-max (Figure 1b ) compared to non-depleted patients.
Discussion
This paper is the ®rst study describing hypermetabolism in such a large group of stable patients with COPD in relation to body composition and lung function. The prevalence of hypermetabolism based on adjustment for FFM amounted to 26% in the patients with COPD. This prevalence was Prevalence of an elevated resting energy expenditure in COPD EC Creutzberg et al surprisingly lower than might be expected on base of earlier studies (Hugli et al, 1993; Fitting et al, 1989; Donahoe et al, 1989; Green & Muers, 1991) . The most common approach to predict REE for an individual in clinical practice is to apply the HB-equations (Harris & Benedict, 1919) , which are based on sex, age, height and body mass. Different studies have investigated hypermetabolism in stable patients with COPD on base of the HB-equations, most studies revealing an increased REE compared to the HB-equations or to a control group (Hugli et al, 1993; Fitting et al, 1989; Donahoe et al, 1989; Green & Muers, 1991) , some not (Sridhar et al, 1994; Ryan et al, 1993) . The disadvantage of all these studies however, is that they described hypermetabolism in relatively small groups of patients (6 ±19 patients), so that the prevalence of hypermetabolism could not be established.
The difference in REE expressed as percentage of the HB-equations between the healthy control group and patients with COPD may in part be caused by differences in the relative amount of FFM between patients and controls, since FFM is the most important determinant of REE. The HB-equations do not take body composition into account, nor do the COPD-speci®c prediction equations of Moore & Angelillo (1988) , which were derived on base of body mass in a group of 43 stable patients with COPD. Considering FFM seems furthermore important in COPD since body compositional changes occur after weight loss. Besides, depletion of FFM despite a normal body mass has been described in patients with COPD (Engelen et al, 1994) . In the present study, FFM explained the variation in REE for 65% in healthy subjects, in agreement with the meta-analyses of Cunningham (1991) and Weinsier et al, (1992) , which both revealed FFM as the best single predictor for REE (R 2 0.65 ± 0.90, R 2 0.92 respectively). Also in our patient group, FFM was identi®ed as the most important predictor of REE (51%). The studies of Green & Muers (1991) and Fitting et al (1989) , which took muscle mass calculated from skinfold thickness into account, found a higher REE divided by muscle mass in patients with COPD compared to healthy subjects. However, by dividing REE by FFM, depleted subjects are incorrectly considered more hypermetabolic than nondepleted subjects, because the intercept in the equation of REE on FFM is not equal to zero. Therefore we adjusted REE for FFM in an age-matched healthy control group as earlier described by Schols et al (1991a) , and applied the derived equations for men and women on the patient group to predict REE.
The prevalence rate of hypermetabolism was shown to be higher in patients with COPD compared to healthy controls. Furthermore, on analysis of variance REE was higher in the patient group compared to the control group after correction for sex, age, FFM and FM. Besides FFM, age was also a signi®cant explaining parameter for the variation in REE in controls and patients. It is known that REE decreases when age increases, which can be predominantly explained by the decline in FFM due to reduced physical activity in elderly people (Vaughan et al, 1991) . This decrease in FFM is possibly accompanied with an alteration in tissue metabolism with age and/or an adaptation in REE due to a lower daily caloric intake (Fukagawa et al, 1990 ) and a decline in physical activity in the elderly (Poehlman, 1992) . Furthermore, although the HB-equations adjust REE for age, it is known that they overestimate hypermetabolism in men over 64 y (Owen et al, 1987) , which was also shown in our elderly control group.
The fact that patients who were hypermetabolic on base of the HB-equations but normometabolic on base of FFM were characterized by a higher age, a lower BMI, FFMI and FMI, brings up the statement that the HB-equations (incorrectly) link hypermetabolism to depletion and aging in patients with COPD, in agreement with several other studies that found a higher REE/REEHB in malnourished patients with COPD compared to adequately nourished patients (Donahoe et al, 1989; Wilson et al, 1990; Schols et al, 1991c) .
The ®nding that REE remained signi®cantly higher in the patient group compared to the healthy control group after analysis of variance with the covariates sex, age, FFM and FM, suggests that other factors in¯uence REE in patients with COPD. Cigarette smoking is considered to have an increasing effect on REE in healthy subjects by the effects of nicotine (Collins et al, 1994 ), but we could not reveal signi®cant differences in the prevalence of smoking between normo-and hypermetabolic patients with COPD.
The suggested increase in oxygen cost of breathing (OCB) is assumed to be one of the main explanations for the elevated REE seen in patients with COPD contributing to weight loss (Donahoe et al, 1989; Sridhar et al, 1994) . However, the artefact of these studies is that OCB was measured by augmenting the ventilation or ventilatory effort and not in rest. O'Donnell postulated recently that increasing the ventilation demands much more energy in patients with COPD than it does in healthy subjects because patients may suffer from dynamic hyperin¯ation (O'Donnell & Webb, 1993) . Dynamic hyperin¯ation will therefore substantially compromise patients with COPD during exercise by elevating the OCB, and as a result total daily energy Prevalence of an elevated resting energy expenditure in COPD EC Creutzberg et al expenditure (TDEE) may be increased. Indeed, a recent study of Baarends et al (1997) revealed an elevated TDEE in stable patients with COPD compared to healthy subjects. The fact that patients with COPD do not show an elevated ventilation in rest makes it however improbable that the OCB is of great impact on REE (O'Donnell & Webb, 1993) . This is furthermore emphazised by the fact that the ef®ciency of breathing measured by imposing resistance did not differ between patients with COPD and healthy subjects (Gosselink et al, 1995) . In the present study we also found no evidence for a higher OCB in hypermetabolic patients compared to normometabolic patients with COPD; instead a tendency towards the opposite direction was seen: the signi®cantly lower TLC found in the hypermetabolic patients indicate that they might be suffering from less air trapping and therefore from less static hyperin¯ation compared to the normometabolic patient group.
The latter ®nding brings up the suggestion that the presence of hypermetabolism may be different for the COPD-subtypes emphysema and chronic bronchitis. On base of the established differences in TLC, the hypermetabolic patients seem to express the more bronchitic form of COPD and the normometabolic patients the emphysematous form. No differences in DLCO, which is the parameter commonly used in clinical practice to distinguish emphysema globally from chronic bronchitis, were however seen between the normo-and hypermetabolic patients. Nevertheless, patients expressing a diminished DLCO are in general characterized by more hyperin¯ation. Green & Muers (1992) discriminated emphysema and chronic bronchitis on base of PaCO 2 and found that measured REE in patients with the postulated bronchitic subtype of COPD (PaCO 2 b 6 kPa) was higher than the predicted REE, while in patients with the suggested emphysematous subtype of COPD (PaCO 2`5 kPa) it was not. Whereas DLCO is a reasonable criterium to subtype COPD in particular in patients with moderate to severe air¯ow obstruction, PaCO 2 is absolutely not; Biernacki et al (1989) investigated the extent of emphysema by measuring lung density using computed tomography scanning and found no relationship between emphysema and PaCO 2 or PaO 2 . Therefore the ®ndings of Green & Muers are disputable, and emphysema and chronic bronchitis must ®rst be adequately differentiated as by use of high resolution computed tomography (HRCT) before drawing preliminary conclusions.
Another possible explanation for the elevated REE seen in patients with COPD may be a thermogenetic effect of bronchodilating agents such as theophyllines and b 2 -sympathicomimetics, which are given in general as an essential part of the pharmacological maintenance treatment approach in patients with COPD. In a previous study we found a signi®cant increase in REE of 11% after nebulization of 5 mg of the b 2 -sympathicomimetic drug salbutamol in younger subjects, but the increase in REE in patients with COPD was only 4% and did not differ from an agematched control group (6%) (Creutzberg et al, 1994) , in line with the rise in REE of 5% found in a comparable study in patients with COPD (Burdet et al, 1997) . Together, these slight effects of salbutamol on REE cannot fully explain the elevated REE in patients with COPD. Furthermore, in the present study the proportion of patients using b 2 -sympathicomimetics or theophyllines was not signi®-cantly different between hypermetabolic and normometabolic patients with COPD.
Hypermetabolism has also been related to the presence of a systemic in¯ammatory response. In an earlier study of our group, elevated levels of the acute phase reactant proteins C-reactive protein (CRP) and LPS-binding protein were reported in hyper-vs normometabolic patients (Schols et al, 1996) , suggesting a link between hypermetabolism and hepatic acute phase response in a part of the patients with COPD.
In order to investigate the relative contribution of hypermetabolism to depletion of FFM in COPD, we determined the prevalence of depletion strati®ed by hypermetabolism (hypermetabolism based on FFM-adjustment), and found a similar prevalence among normo-and hypermetabolic patients. Because no difference was seen in the prevalence of depletion between normo-and hypermetabolic patients, an elevated REE cannot be the sole reason for weight loss and/or loss of FFM in COPD. The fact that FFM-depleted patients were suffering from more hyperination (on base of a higher RV/TLC ratio) and showed a lower PI-max, brings up the suggestion that depleted patients, independently of the presence of hypermetabolism, will express a higher OCB during activities due to more air-trapping and therefore a higher dynamic hyperination. This higher OCB may contribute to the elevated TDEE previously described in patients with COPD compared to healthy age-matched controls independently of REE (Baarends et al, 1997 ). An elevated TDEE will lead to loss of body mass and of FFM when not adequately met by an increase in energy intake, and will ultimately compromise functional performance. The last ®nding implies that analysis of resting energy metabolism alone is not enough for the interpretation of energy balance and body composition in patients with COPD. The eventually enhanced TDEE or energy expenditure for activities should be taken into account when assessing the energy requirements of individual patients in clinical practice.
